CAMP Camp4 Therapeutics Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1736730 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY39.9%
TTM net income YoY-126.8%
TTM EPS YoY-103.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,001.1%
Net margin-2,276.3%
FCF margin-496.4%
EBITDA margin-965.5%
Returns
ROE-146.1%
ROA-109.9%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets20.1%
Debt / equity0.00x
Current ratio6.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-86.7%
Payout ratio—
Capex / revenue16.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $3.50M | $652,000 | $350,000 |
| R&D expense | $38.20M | $38.82M | $40.62M |
| SG&A expense | $17.36M | $14.92M | $11.61M |
| Operating income | -$52.55M | -$53.09M | -$51.88M |
| Income tax | $0 | $0 | $0 |
| Net income | -$80.40M | -$51.79M | -$49.29M |
| EBITDA | -$50.92M | -$51.39M | -$50.20M |
| EPS (basic) | -2.65 | -11.04 | -124.80 |
| EPS (diluted) | -2.65 | -11.04 | -124.80 |
| Dividends declared per share | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 30.38M | 4.69M | 394,976 |
| Balance sheet | |||
| Cash & equivalents | $109.52M | $65.66M | $40.00M |
| Current assets | $114.09M | $66.38M | $40.01M |
| PP&E, net | $2.34M | $3.86M | $4.80M |
| Total assets | $117.81M | $78.31M | $54.95M |
| Current liabilities | $15.51M | $9.60M | $7.81M |
| Total liabilities | $70.10M | $15.16M | $16.53M |
| Shareholders' equity | $47.70M | $63.14M | -$123.73M |
| Shares outstanding | 51.90M | 20.15M | 460,704 |
| Cash flow statement | |||
| Operating cash flow | -$29.55M | -$45.56M | -$44.16M |
| Capital expenditure | $279,000 | $441,000 | $678,000 |
| Free cash flow | -$29.83M | -$46.00M | -$44.83M |
| Investing cash flow | -$243,000 | -$441,000 | -$678,000 |
| Financing cash flow | $75.89M | $71.66M | $301,000 |
| Depreciation & amortization | $1.64M | $1.70M | $1.68M |
| Stock-based compensation | $4.00M | $4.03M | $2.91M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.